GGrantIndex
← Leaderboards

Selna L Kaplan

University Of California San Francisco

$154,794
Attributed
$154,794
Total exposure
6
Grants
0
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding mix

By agency

NIH$154,794 · 6

By mechanism

M01$154,794 · 6

Top collaborators

No co-investigators on record.

Most similar at University Of California San Francisco

Same institution · by research overlap

Others in their field

Top investigators on “Human Therapy Evaluation

Research focus

Human Therapy EvaluationHuman SubjectClinical ResearchChild (0-11)Hormone TherapyDrug Screening /EvaluationEndocrine Disorder ChemotherapyGender DifferenceGonadotropin Releasing FactorHormone Regulation /Control MechanismHuman PubertyPrecocious PubertyPrognosisEndocrine Disorder DiagnosisEndocrine SurgeryFollicle Stimulating HormoneRelapse /RecurrenceSex Development DisorderGonadotropinsHormone AnalogHormone MetabolismSlow Release DrugBone Marrow TransplantationSomatotropin

Grant awards (30)

ENDOCRINE DYSFUNCTION AFTER BONE MARROW TRANSPLANT--CONCOMMITANT CHEMOTHERAPY$0
M01 · FY2002 · RR
EFFICACY OF TRANSSPHENOIDAL SURGERY FOR CUSHING'S DISEASE IN CHILDREN$0
M01 · FY2002 · RR
CHILDREN WITH GROWTH RETARDATION ASSOCIATED WITH BIOINACTIVE GROWTH HORMONE$0
M01 · FY2002 · RR
EVALUATION OF GONADOTROPIN SECRETION IN CHILDREN$0
M01 · FY2002 · RR
EFFICACY AND SAFETY OF LUPRON DEPOT--STERILE LEUPROLIDE ACETATE$0
M01 · FY2002 · RR
USE OF LRF AGONIST FOR TREATMENT OF PRECOCIOUS PUBERTY$0
M01 · FY2002 · RR
EFFICACY AND SAFETY OF LUPRON DEPOT--STERILE LEUPROLIDE ACETATE$0
M01 · FY2001 · RR
ENDOCRINE DYSFUNCTION AFTER BONE MARROW TRANSPLANT--CONCOMMITANT CHEMOTHERAPY$0
M01 · FY2001 · RR
USE OF LRF AGONIST FOR TREATMENT OF PRECOCIOUS PUBERTY$0
M01 · FY2001 · RR
EFFICACY OF TRANSSPHENOIDAL SURGERY FOR CUSHING'S DISEASE IN CHILDREN$0
M01 · FY2001 · RR
CHILDREN WITH GROWTH RETARDATION ASSOCIATED WITH BIOINACTIVE GROWTH HORMONE$0
M01 · FY2001 · RR
EVALUATION OF GONADOTROPIN SECRETION IN CHILDREN$0
M01 · FY2001 · RR
EFFICACY OF TRANSSPHENOIDAL SURGERY FOR CUSHING'S DISEASE IN CHILDREN$25,799
M01 · FY2000 · RR
CHILDREN WITH GROWTH RETARDATION ASSOCIATED WITH BIOINACTIVE GROWTH HORMONE$25,799
M01 · FY2000 · RR
USE OF LRF AGONIST FOR TREATMENT OF PRECOCIOUS PUBERTY$25,799
M01 · FY2000 · RR
ENDOCRINE DYSFUNCTION AFTER BONE MARROW TRANSPLANT--CONCOMMITANT CHEMOTHERAPY$25,799
M01 · FY2000 · RR
EFFICACY AND SAFETY OF LUPRON DEPOT--STERILE LEUPROLIDE ACETATE$25,799
M01 · FY2000 · RR
EVALUATION OF GONADOTROPIN SECRETION IN CHILDREN$25,799
M01 · FY2000 · RR
EFFICACY OF TRANSSPHENOIDAL SURGERY FOR CUSHING'S DISEASE IN CHILDREN$0
M01 · FY2000 · RR
EFFICACY OF TRANSSPHENOIDAL SURGERY FOR CUSHING'S DISEASE IN CHILDREN$0
M01 · FY2000 · RR
EFFICACY AND SAFETY OF LUPRON DEPOT--STERILE LEUPROLIDE ACETATE$0
M01 · FY2000 · RR
EFFICACY AND SAFETY OF LUPRON DEPOT--STERILE LEUPROLIDE ACETATE$0
M01 · FY2000 · RR
ENDOCRINE DYSFUNCTION AFTER BONE MARROW TRANSPLANT--CONCOMMITANT CHEMOTHERAPY$0
M01 · FY2000 · RR
ENDOCRINE DYSFUNCTION AFTER BONE MARROW TRANSPLANT--CONCOMMITANT CHEMOTHERAPY$0
M01 · FY2000 · RR
USE OF LRF AGONIST FOR TREATMENT OF PRECOCIOUS PUBERTY$0
M01 · FY2000 · RR
USE OF LRF AGONIST FOR TREATMENT OF PRECOCIOUS PUBERTY$0
M01 · FY2000 · RR
CHILDREN WITH GROWTH RETARDATION ASSOCIATED WITH BIOINACTIVE GROWTH HORMONE$0
M01 · FY2000 · RR
CHILDREN WITH GROWTH RETARDATION ASSOCIATED WITH BIOINACTIVE GROWTH HORMONE$0
M01 · FY2000 · RR
EVALUATION OF GONADOTROPIN SECRETION IN CHILDREN$0
M01 · FY2000 · RR
EVALUATION OF GONADOTROPIN SECRETION IN CHILDREN$0
M01 · FY2000 · RR